Wound Management News

The FDA’s approval of Baxdela for treating acute bacterial skin and skin structure infections was among the top read articles of the past week on Healio.com/Dermatology.

The FDA announced today that it has approved Baxdela to treat acute bacterial skin and skin structure infections.

Case report study results that Keytruda therapy was associated with eruptive keratoacanthomas in three patients with metastatic squamous cell carcinoma or metastatic melanoma was among recent developments reported on Healio.com/Dermatology.

United States District Judge Kathleen M. Williams for the Southern District of Florida issued a consent decree of permanent injunction against Stratus Pharmaceuticals and Sonar Products, as well as the companies’ officers, Alberto Hoyo and Juan Carlos Billoch, for routinely shipping unapproved, misbranded and substandard or adulterated drugs in interstate commerce, according to a press release issued by the FDA.

Castle Creek Pharmaceuticals announced it has enrolled the first patient in its phase 2/3 clinical trial to measure safety and efficacy of CCP-020, diacerein 1% ointment, for treating epidermolysis bullosa simplex.

NEW ORLEANS — Taksta was noninferior to Zyvox as an oral treatment for acute bacterial skin and skin structure infections, or ABSSSIs, including MRSA, according to phase 3 data presented here.

NEW ORLEANS — Data from two phase 3 trials demonstrated that IV and oral Baxdela had similar safety and efficacy profiles against acute bacterial skin and skin structure infections, or ABSSSIs, compared with a combination regimen of vancomycin and aztreonam among patients with a history of infectious hepatitis.

Researchers found that the microbiome in hidradenitis suppurativa lesional and nonlesional skin differed significantly from the skin of healthy controls, suggesting a link between dysbiotic cutaneous microbiome and the skin disease, according to recently published study results in JAMA Dermatology.

Survey findings that less than half of women assisted their husbands with skin self-examinations was among the top read articles in May on Healio.com/Dermatology.

Patients with non-small cell lung cancer treated with epidermal growth factor receptor inhibitors rarely experienced purpuric skin lesions, which had characteristic clinical and histopathologic presentations, according to study results recently published in JAMA Dermatology.